Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Meropenem dosing in ventilator-associated pneumonia
NCT00050401Phase 3Completed
- Sponsor
- Pfizer
- Start
- Jul 2002
- Primary completion
- Sep 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of meropenem in ventilator-associated pneumonia (VAP), sponsored by Pfizer. Started Jul 2002; status: completed.
02
Drugs
meropenem
03
Conditions
ventilator-associated pneumonia (VAP)
Beyond the preview
Go deeper on NCT00050401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00050401.